Q1 Earnings Forecast for CLDX Issued By Leerink Partnrs

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Celldex Therapeutics in a research note issued on Thursday, February 13th. Leerink Partnrs analyst T. Smith forecasts that the biopharmaceutical company will post earnings per share of ($0.65) for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.94) EPS.

Several other equities research analysts have also commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, UBS Group began coverage on shares of Celldex Therapeutics in a research report on Thursday. They set a “buy” rating and a $44.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.22.

Celldex Therapeutics Trading Down 1.6 %

Shares of Celldex Therapeutics stock opened at $22.70 on Friday. The business has a 50-day moving average price of $24.79 and a two-hundred day moving average price of $29.98. Celldex Therapeutics has a 1-year low of $20.91 and a 1-year high of $53.18. The company has a market cap of $1.51 billion, a P/E ratio of -8.83 and a beta of 1.60.

Hedge Funds Weigh In On Celldex Therapeutics

A number of large investors have recently modified their holdings of the company. KBC Group NV raised its holdings in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares during the last quarter. Invesco Ltd. increased its position in shares of Celldex Therapeutics by 2.1% during the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock worth $1,064,000 after acquiring an additional 871 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the last quarter. Swiss National Bank raised its holdings in shares of Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after acquiring an additional 1,400 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 1,504 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.